We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GEMoaB

News List

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company americanpharmaceuticalreview
June 23, 2021
Blackstone Life Sciences has committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH.
GEMoaB Announces Trial with Solid Tumor Candidate from UniCAR Cellular Immunotherapy Platform americanpharmaceuticalreview
December 24, 2020
GEMoaB has apheresed the first patient in a Phase IA study with UniCAR-T-PSMA, the lead solid tumor product candidate from its proprietary UniCAR cellular immunotherapy platform.
First-in-human universal CAR-T therapy trial begins europeanpharmaceuticalreview
December 08, 2020
The dose-finding trial will evaluate the safety and activity of UniCAR-T-PSMA in up to 16 patients with advanced relapsed/refractory, PSMA-positive solid tumours.
GEMoaB, Intellia Enter Cellular Immunotherapy Research Pact contractpharma
July 21, 2020
Will combine GEMoaB's RevCAR technology platform with Intellia's genome editing technologies to discover and develop allogeneic cellular immunotherapies.